Remembering emil von behring: From tetanus treatment to antibody cooperation with phagocytes
mBio, ISSN: 2150-7511, Vol: 8, Issue: 1
2017
- 50Citations
- 128Captures
- 6Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations50
- Citation Indexes50
- 50
- CrossRef27
- Captures128
- Readers128
- 128
- Mentions6
- References6
- 6
Article Description
A century ago, Emil von Behring passed away. He was the first to be honored by the Nobel Prize for Medicine in 1901 for the successful therapy of diphtheria and tetanus, which he had developed from the bench to the bed. He also contributed to the foundation of immunology, since his therapy was based on passive immunization with specific antisera. Being an ambitious character, he did not shy away from friction with his colleagues Paul Ehrlich and Elias Metchnikoff and his mentor, Robert Koch. Behring was not only an excellent translational researcher but also a successful entrepreneur and early proponent of public-private partnerships.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85014852770&origin=inward; http://dx.doi.org/10.1128/mbio.00117-17; http://www.ncbi.nlm.nih.gov/pubmed/28246359; http://mbio.asm.org/lookup/doi/10.1128/mBio.00117-17; https://syndication.highwire.org/content/doi/10.1128/mBio.00117-17; https://journals.asm.org/doi/10.1128/mBio.00117-17; https://dx.doi.org/10.1128/mbio.00117-17
American Society for Microbiology
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know